qx-314 has been researched along with Bone Cancer in 1 studies
QX-314: triethyl analog of lidocaine; RN & NM refer to ion
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether systemic administration of QX-314 reduces bone cancer pain through selective inhibition of transient receptor potential vanilloid subfamily 1 (TRPV1)-expressing afferents." | 7.83 | Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice. ( Fuseya, S; Kawamata, M; Kawamata, T; Minemura, H; Yamamoto, K; Yamaori, S, 2016) |
| "The aim of this study was to determine whether systemic administration of QX-314 reduces bone cancer pain through selective inhibition of transient receptor potential vanilloid subfamily 1 (TRPV1)-expressing afferents." | 3.83 | Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice. ( Fuseya, S; Kawamata, M; Kawamata, T; Minemura, H; Yamamoto, K; Yamaori, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuseya, S | 1 |
| Yamamoto, K | 1 |
| Minemura, H | 1 |
| Yamaori, S | 1 |
| Kawamata, T | 1 |
| Kawamata, M | 1 |
1 other study available for qx-314 and Bone Cancer
| Article | Year |
|---|---|
Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice.
Topics: Anesthetics, Local; Animals; Behavior, Animal; Bone Neoplasms; Cyclic AMP Response Element-Binding P | 2016 |